Xenon Pharmaceuticals (XENE) Profit After Tax (2013 - 2026)
Xenon Pharmaceuticals (XENE) reported Profit After Tax of -$102.3 million for Q1 2026, down 57.27% year-over-year from -$239.4 million in Q1 2025, and up 2.81% quarter-over-quarter from -$105.3 million in Q4 2025.
Xenon Pharmaceuticals (XENE) Profit After Tax (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has 14 years of Profit After Tax data on file, last reported at -$102.3 million in Q1 2026.
- Profit After Tax for Q1 2026 came in at -$102.3 million, down 57.27% year-over-year; the trailing twelve-month figure through Mar 2026 was -$383.2 million (down 52.38% YoY), and the FY2025 annual result was -$345.9 million, down 47.62% from the prior year.
- Profit After Tax grew to -$102.3 million in Q1 2026 per XENE's latest filing, from -$105.3 million in the prior quarter.
- Over five years, Profit After Tax peaked at -$19.7 million in Q1 2022 and troughed at -$105.3 million in Q4 2025.
- A 5-year average of -$58.3 million and a median of -$48.5 million in 2023 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2022 and 2024: Profit After Tax slumped 140.53% in 2022, then decreased 14.87% in 2024.
- A 5-year view of Profit After Tax shows it stood at -$37.4 million in 2022, then retreated by 19.65% to -$44.7 million in 2023, then slumped by 46.81% to -$65.7 million in 2024, then sank by 60.25% to -$105.3 million in 2025, then advanced by 2.81% to -$102.3 million in 2026.
- Business Quant data shows XENE's Profit After Tax at -$102.3 million in Q1 2026, -$105.3 million in Q4 2025, and -$90.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.74 Mn |
| 10 | Xenon Pharmaceuticals | 4.61 Bn | 4.61 Bn | - | -102.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -102.30 Mn |
| Dec 31, 2025 | -105.26 Mn |
| Sep 30, 2025 | -90.90 Mn |
| Jun 30, 2025 | -84.71 Mn |
| Mar 31, 2025 | -65.05 Mn |
| Dec 31, 2024 | -65.69 Mn |
| Sep 30, 2024 | -62.79 Mn |
| Jun 30, 2024 | -57.92 Mn |
| Mar 31, 2024 | -47.93 Mn |
| Dec 31, 2023 | -44.74 Mn |
| Sep 30, 2023 | -48.46 Mn |
| Jun 30, 2023 | -47.46 Mn |
| Mar 31, 2023 | -41.73 Mn |
| Dec 31, 2022 | -37.40 Mn |
| Sep 30, 2022 | -37.15 Mn |
| Jun 30, 2022 | -31.16 Mn |
| Mar 31, 2022 | -19.67 Mn |
| Dec 31, 2021 | -25.56 Mn |
| Sep 30, 2021 | -15.45 Mn |
| Jun 30, 2021 | -22.11 Mn |